Q3 EPS Forecast for ArriVent BioPharma Increased by Analyst

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Lifesci Capital raised their Q3 2025 earnings per share (EPS) estimates for shares of ArriVent BioPharma in a note issued to investors on Monday, July 21st. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings per share of ($0.66) for the quarter, up from their prior forecast of ($0.74). The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma's Q4 2025 earnings at ($0.68) EPS, FY2025 earnings at ($3.90) EPS and FY2026 earnings at ($3.68) EPS.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($1.24).

AVBP has been the subject of several other reports. Oppenheimer reaffirmed an "outperform" rating and issued a $44.00 target price (up from $39.00) on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of ArriVent BioPharma in a research note on Tuesday. The Goldman Sachs Group reiterated a "buy" rating and issued a $33.00 price objective on shares of ArriVent BioPharma in a research note on Thursday, July 10th. Jones Trading initiated coverage on ArriVent BioPharma in a report on Tuesday, May 20th. They set a "buy" rating and a $40.00 price objective on the stock. Finally, Guggenheim reaffirmed a "buy" rating and set a $45.00 price objective on shares of ArriVent BioPharma in a research note on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $39.29.

ArriVent BioPharma Stock Down 1.3%

Shares of AVBP traded down $0.27 during midday trading on Wednesday, reaching $21.18. The company had a trading volume of 146,152 shares, compared to its average volume of 253,124. The stock has a market cap of $724.57 million, a PE ratio of -5.62 and a beta of 1.20. ArriVent BioPharma has a 1-year low of $15.47 and a 1-year high of $36.37. The firm has a 50 day simple moving average of $22.09 and a 200-day simple moving average of $22.31.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its stake in shares of ArriVent BioPharma by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 206,379 shares of the company's stock worth $5,498,000 after acquiring an additional 4,011 shares in the last quarter. Swiss National Bank bought a new stake in shares of ArriVent BioPharma in the 4th quarter worth approximately $703,000. Intech Investment Management LLC acquired a new position in shares of ArriVent BioPharma in the 4th quarter worth approximately $394,000. KLP Kapitalforvaltning AS acquired a new position in shares of ArriVent BioPharma in the 4th quarter worth approximately $83,000. Finally, Vanguard Group Inc. raised its holdings in shares of ArriVent BioPharma by 5.3% in the 4th quarter. Vanguard Group Inc. now owns 1,417,291 shares of the company's stock worth $37,757,000 after buying an additional 71,741 shares in the last quarter. 9.48% of the stock is owned by institutional investors and hedge funds.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.